E. Serra‐Baldrich
About
In The Last Decade
E. Serra‐Baldrich
77 papers receiving 877 citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Dermatology 674
- Immunology and Allergy 285
- Rheumatology 117
- Public Health, Environmental and Occupational Health 98
- Physiology 86
Countries citing papers authored by E. Serra‐Baldrich
This map shows the geographic impact of E. Serra‐Baldrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Serra‐Baldrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Serra‐Baldrich more than expected).
Fields of papers citing papers by E. Serra‐Baldrich
This network shows the impact of papers produced by E. Serra‐Baldrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Serra‐Baldrich. The network helps show where E. Serra‐Baldrich may publish in the future.
Co-authorship network of co-authors of E. Serra‐Baldrich
This figure shows the co-authorship network connecting the top 25 collaborators of E. Serra‐Baldrich. A scholar is included among the top collaborators of E. Serra‐Baldrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Serra‐Baldrich. E. Serra‐Baldrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | 32 | |
| 6 | Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials breakdown → | 72 |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 5 | |
| 10 | 8 | |
| 11 | Manejo de la urticaria en urgencias: recomendaciones de un grupo multidisciplinar de expertos. | 0 |
| 12 | Agentes biológicos aprobados y en desarrollo clínico para el tratamiento de la dermatitis atópica | 1 |
| 13 | 12 | |
| 14 | 5 | |
| 15 | 13 | |
| 16 | Sarcoidosis (II): Inmunopatogénesis. Criterios de actividad. Conclusión | 1 |
| 17 | 5 | |
| 18 | 10 | |
| 19 | 56 | |
| 20 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.